FierceBiotechOriginal article
{"a":[{"_":"Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseases","$":{"href":"/biotech/ascidian-lilly-lock-19b-renal-disease-research-collaboration","hreflang":"en"}}]}
PartnershipRNA exon editing therapeuticsPositive
AI Analysis
Summary
Ascidian Therapeutics and Eli Lilly have entered into a research collaboration worth up to $1.9 billion for discovering and developing RNA exon editing therapeutics for genetic kidney diseases.
Importance:7/10
Sentiment:
0.70
partnershipcollaborationRNA exon editingkidney diseasegenetic disease
Related Companies
Read the original article
Published by FierceBiotech on June 2, 2026 2:50 PM